Login / Signup

A Scale to Assess Activities of Daily Living in Pantothenate Kinase-Associated Neurodegeneration.

Randall D MarshallAbigail CollinsMaria L EscolarH A JinnahFlorentine RadelfahrMichael C KruerAleksandar VidenovicAmy Robichaux-ViehoeverLaura SwettDennis A RevickiRandall H BenderWilliam R Lenderking
Published in: Movement disorders clinical practice (2019)
The PKAN-ADL scale demonstrated acceptable content validity, with evidence of construct validity and excellent reliability. Overall results support the use of the PKAN-ADL scale in clinical trials.
Keyphrases
  • clinical trial
  • randomized controlled trial
  • tyrosine kinase
  • open label
  • phase ii
  • study protocol
  • double blind